MX2009013976A - Compuestos imidazotiazol moduladores de sirtuina. - Google Patents

Compuestos imidazotiazol moduladores de sirtuina.

Info

Publication number
MX2009013976A
MX2009013976A MX2009013976A MX2009013976A MX2009013976A MX 2009013976 A MX2009013976 A MX 2009013976A MX 2009013976 A MX2009013976 A MX 2009013976A MX 2009013976 A MX2009013976 A MX 2009013976A MX 2009013976 A MX2009013976 A MX 2009013976A
Authority
MX
Mexico
Prior art keywords
diseases
sirtuin
disorders
modulating
sirtuin modulating
Prior art date
Application number
MX2009013976A
Other languages
English (en)
Spanish (es)
Inventor
Jean Bemis
Walter Joseph Lunsmann
Jeremy S Disch
Michael Jirousek
Pui Yee Ng
Chi B Vu
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009013976(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of MX2009013976A publication Critical patent/MX2009013976A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2009013976A 2007-06-20 2008-06-20 Compuestos imidazotiazol moduladores de sirtuina. MX2009013976A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93663307P 2007-06-20 2007-06-20
PCT/US2008/007771 WO2008156866A1 (en) 2007-06-20 2008-06-20 Sirtuin modulating imidazothiazole compounds

Publications (1)

Publication Number Publication Date
MX2009013976A true MX2009013976A (es) 2010-04-27

Family

ID=39810276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013976A MX2009013976A (es) 2007-06-20 2008-06-20 Compuestos imidazotiazol moduladores de sirtuina.

Country Status (26)

Country Link
US (2) US7829556B2 (enExample)
EP (1) EP2167510B1 (enExample)
JP (1) JP5281081B2 (enExample)
KR (1) KR101525268B1 (enExample)
CN (1) CN101874031B (enExample)
AR (1) AR067106A1 (enExample)
AU (1) AU2008266746B2 (enExample)
BR (1) BRPI0813653A2 (enExample)
CA (1) CA2692099C (enExample)
CL (1) CL2008001821A1 (enExample)
CO (1) CO6261382A2 (enExample)
CR (1) CR11231A (enExample)
DO (1) DOP2009000283A (enExample)
EA (1) EA018182B1 (enExample)
ES (1) ES2534544T3 (enExample)
IL (1) IL202729A (enExample)
MA (1) MA31568B1 (enExample)
MX (1) MX2009013976A (enExample)
MY (1) MY149316A (enExample)
NZ (1) NZ581989A (enExample)
PE (1) PE20090423A1 (enExample)
TW (1) TW200918542A (enExample)
UA (1) UA104127C2 (enExample)
UY (1) UY31170A1 (enExample)
WO (1) WO2008156866A1 (enExample)
ZA (1) ZA200908882B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1853610A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
WO2007041643A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CL2008001821A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
US8391970B2 (en) * 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2009099643A1 (en) * 2008-02-07 2009-08-13 The J. David Gladstone Institutes Use of sirt1 activators or inhibitors to modulate an immune response
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
JP5425891B2 (ja) 2008-05-01 2014-02-26 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのキノリンおよび関連する類似体
AU2009266889B2 (en) * 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
CN102227420B (zh) 2008-09-29 2015-06-24 西特里斯药业公司 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
WO2010077642A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
JP5628828B2 (ja) 2008-12-19 2014-11-19 サートリス ファーマシューティカルズ， インコーポレイテッド チアゾロピリジンサーチュイン調節化合物
US20110054569A1 (en) * 2009-09-01 2011-03-03 Zitnik Ralph J Prescription pad for treatment of inflammatory disorders
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
EA201290194A1 (ru) 2009-11-06 2013-04-30 Дзе Дж. Дейвид Гладстоун Инститьютс Способы и композиции для модулирования уровня тау-полипептида
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) * 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
WO2011130595A2 (en) 2010-04-15 2011-10-20 Sirtris Pharmaceuticals, Inc. Sirtuin activators and activation assays
RU2693462C2 (ru) * 2010-05-03 2019-07-03 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
WO2011143317A2 (en) * 2010-05-11 2011-11-17 President And Fellows Of Harvard College Methods for the regulation of cellular metabolism through the modulation of sirt3 activity
EP2670404B1 (en) 2011-02-02 2018-08-29 The Trustees of Princeton University Sirtuin modulators as virus production modulators
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
PH12014500198A1 (en) 2011-07-15 2017-02-10 Nusirt Sciences Inc Compositions and methods for modulating metabolic pathways
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013090645A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
US9585876B2 (en) 2013-03-15 2017-03-07 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
WO2015002892A1 (en) * 2013-07-01 2015-01-08 Meier Joshua Abraham Methods of treating diseases by modulating mitochondrial dna deletions
JP2017506651A (ja) 2014-02-27 2017-03-09 ニューサート サイエンシーズ， インコーポレイテッド 脂肪肝の低減または予防のための組成物および方法
WO2015186068A1 (en) 2014-06-02 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Preparation and use of crystalline beta-d-nicotinamide riboside
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
KR101839688B1 (ko) 2015-08-21 2018-03-19 중앙대학교 산학협력단 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017123161A1 (en) * 2016-01-15 2017-07-20 Agency For Science, Technology And Research Inhibition of intracellular growth of mycobacterium species and its applications
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2017147180A1 (en) 2016-02-22 2017-08-31 The Trustees Of The University Of Pennsylvania Methods for enhancing liver regeneration
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN109700790A (zh) * 2018-12-28 2019-05-03 中南大学湘雅医院 一种靶向AQP3的抗皮肤衰老药物Butein
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
CN111000854B (zh) * 2019-12-30 2023-06-09 昆药集团股份有限公司 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
KR20250039366A (ko) * 2022-06-17 2025-03-20 코다젠 바이오사이언시스 인코포레이티드 시르투인 활성화 화합물을 포함하는 시르투인 조절 화합물, 및 이의 응용
US12012370B1 (en) 2022-12-29 2024-06-18 Codagen Biosciences, Inc. Sirtuin modulating compounds and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
US3517007A (en) 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
ZA735753B (en) 1972-09-14 1974-07-31 American Cyanamid Co Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles
US4018932A (en) 1975-11-03 1977-04-19 American Cyanamid Company Anthelmintic pour-on formulations for topical use on domestic and farm animals
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
JPH0576084A (ja) 1991-09-11 1993-03-26 Matsushita Electric Ind Co Ltd 遠隔表示装置
JPH05289689A (ja) 1992-04-06 1993-11-05 Sanyo Electric Co Ltd 可搬性規則音声合成装置
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
JP2005298333A (ja) 2001-11-15 2005-10-27 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
JP2006519833A (ja) 2003-03-11 2006-08-31 ファイザー・プロダクツ・インク トランスフォーミング成長因子（ｔｇｆ）阻害剤としてのピラジン化合物
JP2006519791A (ja) 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
DE602004026629D1 (de) 2003-12-15 2010-05-27 Japan Tobacco Inc Cyclopropanderivate und ihre pharmazeutische verwendung
US7714161B2 (en) 2004-01-20 2010-05-11 Brigham Young University Sirtuin activating compounds and methods for making the same
MXPA06012059A (es) 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
PT1755391E (pt) * 2004-06-04 2016-02-03 Univ Washington Métodos e composições para o tratamento de neuropatias
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
EP1853610A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
KR20080019213A (ko) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2618370A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CN101910184A (zh) 2007-11-08 2010-12-08 西特里斯药业公司 可溶性噻唑并吡啶
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
CA2692099A1 (en) 2008-12-24
JP5281081B2 (ja) 2013-09-04
TW200918542A (en) 2009-05-01
EA201070034A1 (ru) 2010-06-30
MY149316A (en) 2013-08-30
AR067106A1 (es) 2009-09-30
ES2534544T3 (es) 2015-04-24
CN101874031B (zh) 2013-02-20
PE20090423A1 (es) 2009-04-18
BRPI0813653A2 (pt) 2014-12-30
US20110015192A1 (en) 2011-01-20
KR20100038093A (ko) 2010-04-12
DOP2009000283A (es) 2011-03-31
AU2008266746A1 (en) 2008-12-24
CL2008001821A1 (es) 2009-03-13
JP2010530431A (ja) 2010-09-09
CN101874031A (zh) 2010-10-27
WO2008156866A1 (en) 2008-12-24
IL202729A (en) 2013-10-31
US8247565B2 (en) 2012-08-21
NZ581989A (en) 2012-06-29
CO6261382A2 (es) 2011-03-22
CR11231A (es) 2012-05-16
KR101525268B1 (ko) 2015-06-02
US7829556B2 (en) 2010-11-09
MA31568B1 (fr) 2010-08-02
IL202729A0 (en) 2010-06-30
UY31170A1 (es) 2009-01-30
EA018182B1 (ru) 2013-06-28
EP2167510A1 (en) 2010-03-31
ZA200908882B (en) 2010-08-25
CA2692099C (en) 2016-08-09
AU2008266746B2 (en) 2012-03-15
US20090012080A1 (en) 2009-01-08
EP2167510B1 (en) 2015-02-25
UA104127C2 (en) 2014-01-10

Similar Documents

Publication Publication Date Title
MX2009013976A (es) Compuestos imidazotiazol moduladores de sirtuina.
MX2009013977A (es) Compuestos de tiazolopiridina moduladores de sirtuinas.
MY160006A (en) Thiazolopyridine sirtuin modulating compounds
IN2012DN03799A (enExample)
EP2344475A4 (en) QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
MX2010005186A (es) Tiazolopiridinas solubilizadas.
WO2006094209A3 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
MX2011009213A (es) Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
WO2007019344A8 (en) Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds
WO2006105440A3 (en) Nicotinamide riboside and analogues thereof
WO2014186313A8 (en) Substituted bridged urea analogs as sirtuin modulators
EA201170137A1 (ru) Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина
WO2008100376A3 (en) Truncation variants of sirt1 and methods of use thereof
WO2006078941A3 (en) Novel sirtuin activating compounds and methods of use thereof
WO2006094237A3 (en) Acridine and quinoline dervatives as sirtuin modulators
WO2006094210A3 (en) Tetrahydroquinoxalinone sirtuin modulators
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
WO2006094246A3 (en) N-arylmethyl benzamide sirtuin modulators
TH110888A (th) สารประกอบที่มอดูเลทเซอทูอิน

Legal Events

Date Code Title Description
FG Grant or registration